Fuji Pharma Co., Ltd. (JP:4554)
:4554
Want to see JP:4554 full AI Analyst Report?
4554 Stock Chart & Stats
¥1888.00
-¥22.00(-1.41%)
At close: 4:00 PM EST
¥1888.00
-¥22.00(-1.41%)
Day’s Range― - ―
52-Week Range¥1,233.00 - ¥2,559.00
Previous CloseN/A
Volume88.50K
Average Volume (3M)86.41K
Market Cap
¥59.68B
Enterprise Value¥83.05B
Total Cash (Recent Filing)¥7.25B
Total Debt (Recent Filing)¥30.94B
Price to Earnings (P/E)35.6
Beta0.87
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.39%
Share Statistics
EPS (TTM)13.28
Shares Outstanding26,541,100
10 Day Avg. Volume111,080
30 Day Avg. Volume86,410
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)0.80
Price to Sales (P/S)0.73
P/FCF Ratio9.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)152.3
Revenue Forecast (FY)¥53.93B
Bulls Say, Bears Say
Bulls Say
Niche Therapeutic Focus & CDMO ServicesFuji Pharma’s specialization in women’s health plus contract manufacturing provides durable revenue diversification. Branded/licensed prescription sales leverage stable prescription demand, while CDMO work offers multi-client production contracts and backlog visibility, cushioning cyclicality and supporting steady cash flows.
Consistent Revenue GrowthSustained top-line expansion signals product adoption and effective commercial execution. Consistent revenue growth enhances scale economics, underpins R&D investment and supports longer-term contractual relationships with hospitals and wholesalers, improving resilience versus single-period fluctuations.
Improving Free Cash FlowRising free cash flow strengthens internal funding for capex, R&D or debt reduction and increases financial flexibility. An improved FCF to net income ratio indicates better cash conversion over time, which supports sustainable operations, potential reinvestment, and resilience through industry cycles.
Bears Say
Rising LeverageElevated and rising debt levels reduce balance sheet flexibility and increase interest burden risk. Higher leverage constrains capacity to fund new programs or absorb reimbursement shocks, raises refinancing and covenant exposure, and can amplify downside in slower revenue periods.
Margin Volatility And Recent WeaknessVolatile and weakening EBIT and net margins suggest cost pressures or adverse pricing/reimbursement dynamics. Margin instability undermines predictable cash generation, makes long-term planning harder, and can erode returns on R&D and manufacturing investments over multiple periods.
Weak Operating Cash ConversionIf operating cash lags reported earnings, underlying working capital strains or non-cash accounting items may limit liquidity. Weak cash conversion increases reliance on external financing to fund growth or service debt, exacerbating risks from the company’s rising leverage profile.
Fuji Pharma Co., Ltd. News
4554 FAQ
What was Fuji Pharma Co., Ltd.’s price range in the past 12 months?
Fuji Pharma Co., Ltd. lowest stock price was ¥1233.00 and its highest was ¥2559.00 in the past 12 months.
What is Fuji Pharma Co., Ltd.’s market cap?
Fuji Pharma Co., Ltd.’s market cap is ¥59.68B.
When is Fuji Pharma Co., Ltd.’s upcoming earnings report date?
Fuji Pharma Co., Ltd.’s upcoming earnings report date is May 12, 2026 which is in 16 days.
How were Fuji Pharma Co., Ltd.’s earnings last quarter?
Fuji Pharma Co., Ltd. released its earnings results on Feb 05, 2026. The company reported ¥13.28 earnings per share for the quarter, beating the consensus estimate of N/A by ¥13.28.
Is Fuji Pharma Co., Ltd. overvalued?
According to Wall Street analysts Fuji Pharma Co., Ltd.’s price is currently Overvalued.
Does Fuji Pharma Co., Ltd. pay dividends?
Fuji Pharma Co., Ltd. pays a Semiannually dividend of ¥25.5 which represents an annual dividend yield of 2.39%. See more information on Fuji Pharma Co., Ltd. dividends here
What is Fuji Pharma Co., Ltd.’s EPS estimate?
Fuji Pharma Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fuji Pharma Co., Ltd. have?
Fuji Pharma Co., Ltd. has 26,541,100 shares outstanding.
What happened to Fuji Pharma Co., Ltd.’s price movement after its last earnings report?
Fuji Pharma Co., Ltd. reported an EPS of ¥13.28 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.157%.
Which hedge fund is a major shareholder of Fuji Pharma Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4554
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fuji Pharma Co., Ltd.
Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women; in vitro diagnostics, acute medical care products, and curative medicines; and information regarding pharmaceuticals and health. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.
Technical Analysis
Mochida Pharmaceutical Co., Ltd.
―
Fuso Pharmaceutical Industries,Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
Daito Pharmaceutical Co., Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---